| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/17/2001 | EP1144411A1 Antihistaminic spiro compounds |
| 10/17/2001 | EP1144410A2 Use of imidazo 1,5-a]-pyrido 3,2-e]-pyrazinones as medicaments |
| 10/17/2001 | EP1144409A2 Phenyl urea and phenyl thiourea derivatives |
| 10/17/2001 | EP1144408A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application |
| 10/17/2001 | EP1144406A1 Antifungal azole derivatives having a fluorinated vinyl group and process for preparing same |
| 10/17/2001 | EP1144405A1 Triazole compounds with dopamine-d3-receptor affinity |
| 10/17/2001 | EP1144404A1 Piperidinylquinolines as protein tyrosine kinase inhibitors |
| 10/17/2001 | EP1144403A1 Substitued pyrazoles as p38 kinase inhibitors |
| 10/17/2001 | EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 10/17/2001 | EP1144399A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group |
| 10/17/2001 | EP1144397A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group |
| 10/17/2001 | EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 10/17/2001 | EP1144395A1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 10/17/2001 | EP1144394A1 1-heterocycle substituted diarylamines |
| 10/17/2001 | EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor |
| 10/17/2001 | EP1144390A2 Kinase inhibitors |
| 10/17/2001 | EP1144389A1 Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoicacid]calcium salt |
| 10/17/2001 | EP1144388A1 Acyl derivatives which treat vla-4 related disorders |
| 10/17/2001 | EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 10/17/2001 | EP1144386A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament |
| 10/17/2001 | EP1144385A1 Benzoheterocycles and their use as mek inhibitors |
| 10/17/2001 | EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/17/2001 | EP1144381A2 Substituted benzo[de]isoquinoline-1,3-diones |
| 10/17/2001 | EP1144377A1 Oxetanone derivatives |
| 10/17/2001 | EP1144373A2 Serine protease inhibitors |
| 10/17/2001 | EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 10/17/2001 | EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors |
| 10/17/2001 | EP1144370A2 Thyroid receptor ligands |
| 10/17/2001 | EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 10/17/2001 | EP1144368A2 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| 10/17/2001 | EP1144366A2 Use of androgen receptor suppressors |
| 10/17/2001 | EP1144365A2 Inhibitors of alpha-4 beta-1 mediated cell adhesion |
| 10/17/2001 | EP1144364A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/17/2001 | EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 10/17/2001 | EP1144361A1 Method for reducing 3-dimethylamino-2-phenylpropion-acid ethyl ester-content in solutions of 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylic acid ethyl ester |
| 10/17/2001 | EP1144348A2 Lta 4? hydrolase inhibitors |
| 10/17/2001 | EP1144305A1 NOVEL sPLA 2 INHIBITORS |
| 10/17/2001 | EP1144065A1 Apparatus and process for preparing crystalline particles |
| 10/17/2001 | EP1144050A2 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 10/17/2001 | EP1144011A2 Prodrug compounds and process for preparation thereof |
| 10/17/2001 | EP1144005A1 Treatment of papillomavirus infections |
| 10/17/2001 | EP1144003A1 Methods and devices for delivery of agents to breast milk ducts |
| 10/17/2001 | EP1144000A1 New dialysis method |
| 10/17/2001 | EP1143991A2 Inhibitors of h+k+ -atpase |
| 10/17/2001 | EP1143988A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 10/17/2001 | EP1143987A1 Natural composition and method for the treatment of sexual dysfunction |
| 10/17/2001 | EP1143981A1 Treatment and prevention of hiv and other viral infections |
| 10/17/2001 | EP1143979A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes |
| 10/17/2001 | EP1143978A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 10/17/2001 | EP1143977A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 10/17/2001 | EP1143976A2 Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 10/17/2001 | EP1143975A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 10/17/2001 | EP1143974A1 Pharmaceutical compositions for alleviating discomfort |
| 10/17/2001 | EP1143973A2 Compositions having improved stability |
| 10/17/2001 | EP1143972A1 Prevention and treatment of migraine and other recurrent headaches using leukotriene ltd4 receptor blocker drugs |
| 10/17/2001 | EP1143971A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use |
| 10/17/2001 | EP1143970A1 Pyridine compounds, use and preparation thereof |
| 10/17/2001 | EP1143969A1 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 10/17/2001 | EP1143968A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 10/17/2001 | EP1143967A2 Use of anticonvulsant derivatives for treating cluster headaches |
| 10/17/2001 | EP1143966A1 Preparation for warts |
| 10/17/2001 | EP1143965A1 Carbocyclic potassium channel inhibitors |
| 10/17/2001 | EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
| 10/17/2001 | EP1143963A1 Multiparticulate bisoprolol formulation |
| 10/17/2001 | EP1143962A1 Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent |
| 10/17/2001 | EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto |
| 10/17/2001 | EP1143960A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 10/17/2001 | EP1143959A2 Antifungal activity of dicationic molecules |
| 10/17/2001 | EP1143958A2 Pharmaceutical composition and use of rnsaid for treating inflammation |
| 10/17/2001 | EP1143957A2 Treatment of arthritis with mek inhibitors |
| 10/17/2001 | EP1143956A2 Compositions and methods for the treatment of anorectal disorders |
| 10/17/2001 | EP1143955A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 10/17/2001 | EP1143954A2 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| 10/17/2001 | EP1143953A2 Method of inhibiting angiogenesis |
| 10/17/2001 | EP1143952A2 Method and composition for treating and preventing tuberculosis |
| 10/17/2001 | EP1143951A2 Antimalarial agents |
| 10/17/2001 | EP1143950A2 Topical application products |
| 10/17/2001 | EP1143949A2 19-nor-vitamin d3 compounds with calcemic activity |
| 10/17/2001 | EP1143948A2 Liver-selective glucocorticoid antagonist for treating diabetes |
| 10/17/2001 | EP1143947A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 10/17/2001 | EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 10/17/2001 | EP1143945A2 Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry |
| 10/17/2001 | EP1143944A2 Use of arylalkanoylpyridazines |
| 10/17/2001 | EP1143943A2 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
| 10/17/2001 | EP1143942A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 10/17/2001 | EP1143941A2 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections |
| 10/17/2001 | EP1143940A2 Compositions and methods for mucosal delivery |
| 10/17/2001 | EP1143938A2 Phinan |
| 10/17/2001 | EP1143937A2 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| 10/17/2001 | EP1143936A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN $g(a)-ANTAGONIST |
| 10/17/2001 | EP1143935A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 10/17/2001 | EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 10/17/2001 | EP1143930A2 Pharmaceutical formulation of fluticasone propionate |
| 10/17/2001 | EP1143928A1 Milling process for the production of finely milled medicinal substances |
| 10/17/2001 | EP1143927A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 10/17/2001 | EP1143925A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 10/17/2001 | EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system |
| 10/17/2001 | EP1143917A2 Anticonvulsant derivatives useful in treating post traumatic stress disorder |
| 10/17/2001 | EP1143916A2 Topical compositions comprising protected functional thiols |
| 10/17/2001 | EP1143896A1 Methods of hydrating mucosal surfaces |